World News

The companies will combine Evotec’s screening technologies, compound libraries and AI-enabled discovery platform with Odyssey’s expertise in the biology of autoimmune and inflammatory diseases.

Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.

Under the collaboration, Chugai scientists will use Biomni Lab to bring together AI capabilities and diverse biomedical resources within the company’s research environment.

Moderna expects to make mFlusiva available in the U.S. ahead of the 2026-2027 respiratory virus season.

Alteogen designed Hybrozyme to help convert biologic medicines that are traditionally administered through intravenous infusion into subcutaneous formulations.

Novo Nordisk will also use H1’s technology to support several aspects of clinical research, including trial design, patient enrollment and clinical trial site selection.

The newly raised capital will enable Inocras to expand its commercial operations and clinical infrastructure across the United States.

The company’s scientific capabilities include chimeric antigen receptor T-cell (CAR-T) therapies and treatments derived from induced pluripotent stem cells (iPSCs).